Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2023)

Historic Current Deferred Revenue for Denali Therapeutics (DNLI) over the last 7 years, with Q2 2023 value amounting to $1.3 million.

  • Denali Therapeutics' Current Deferred Revenue changed N/A to $1.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $290.1 million for FY2022, which is 93905.79% up from last year.
  • Denali Therapeutics' Current Deferred Revenue amounted to $1.3 million in Q2 2023.
  • Denali Therapeutics' 5-year Current Deferred Revenue high stood at $290.4 million for Q1 2023, and its period low was $23000.0 during Q3 2022.
  • Its 5-year average for Current Deferred Revenue is $51.2 million, with a median of $21.3 million in 2019.
  • Examining YoY changes over the last 5 years, Denali Therapeutics' Current Deferred Revenue showed a top increase of 93905.79% in 2022 and a maximum decrease of 9826.28% in 2022.
  • Quarter analysis of 5 years shows Denali Therapeutics' Current Deferred Revenue stood at $18.7 million in 2019, then grew by 6.27% to $19.9 million in 2020, then soared by 40.18% to $27.9 million in 2021, then soared by 939.06% to $290.1 million in 2022, then tumbled by 99.55% to $1.3 million in 2023.
  • Its Current Deferred Revenue stands at $1.3 million for Q2 2023, versus $290.4 million for Q1 2023 and $290.1 million for Q4 2022.